Ingersoll-Rand Plc (IR) Forms $88.82 Double Bottom; Repros Therapeutics Has 0.7 Sentiment

March 9, 2018 - By rebbecca

Ingersoll-Rand Plc (IR) formed double bottom with $86.16 target or 3.00% below today’s $88.82 share price. Ingersoll-Rand Plc (IR) has $22.20 billion valuation. The stock increased 1.53% or $1.34 during the last trading session, reaching $88.82. About 794,926 shares traded. Ingersoll-Rand Plc (NYSE:IR) has risen 39.42% since March 9, 2017 and is uptrending. It has outperformed by 22.72% the S&P500.

Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of various drugs to treat hormonal and reproductive system disorders for male and female in the United States. The company has market cap of $26.51 million. The Company’s product portfolio include Proellex that is in Phase III clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis; and enclomiphene, a single isomer of clomiphene citrate, which is in Phase III clinical trials for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. It currently has negative earnings.

Among 23 analysts covering Ingersoll-Rand Plc (NYSE:IR), 13 have Buy rating, 0 Sell and 10 Hold. Therefore 57% are positive. Ingersoll-Rand Plc has $115.0 highest and $53 lowest target. $91.17’s average target is 2.65% above currents $88.82 stock price. Ingersoll-Rand Plc had 72 analyst reports since July 30, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Sector Perform” rating and $76 target in Thursday, October 27 report. The rating was maintained by Robert W. Baird on Wednesday, January 31 with “Hold”. The firm has “Buy” rating given on Monday, August 3 by Argus Research. The company was maintained on Thursday, October 26 by RBC Capital Markets. CLSA downgraded Ingersoll-Rand Plc (NYSE:IR) on Monday, April 4 to “Outperform” rating. The stock of Ingersoll-Rand Plc (NYSE:IR) earned “Neutral” rating by Buckingham Research on Wednesday, November 16. RBC Capital Markets maintained it with “Hold” rating and $8500 target in Monday, July 10 report. BMO Capital Markets maintained it with “Buy” rating and $10500 target in Tuesday, July 18 report. The firm has “Buy” rating by Nomura given on Monday, March 7. RBC Capital Markets maintained it with “Hold” rating and $98.0 target in Wednesday, January 31 report.

Investors sentiment decreased to 1.04 in Q3 2017. Its down 0.12, from 1.16 in 2017Q2. It worsened, as 41 investors sold Ingersoll-Rand Plc shares while 190 reduced holdings. 77 funds opened positions while 191 raised stakes. 202.31 million shares or 0.64% more from 201.02 million shares in 2017Q2 were reported. Heritage Wealth Advisors has 0.17% invested in Ingersoll-Rand Plc (NYSE:IR) for 3,746 shares. Koch stated it has 12,599 shares or 0.27% of all its holdings. Highstreet Asset Mngmt has invested 0.06% in Ingersoll-Rand Plc (NYSE:IR). Panagora Asset Management holds 0.69% in Ingersoll-Rand Plc (NYSE:IR) or 1.95 million shares. Segall Bryant & Hamill Lc stated it has 0.35% in Ingersoll-Rand Plc (NYSE:IR). Ifc Holding Inc Fl has 4,578 shares for 0.03% of their portfolio. 16.76 million were accumulated by Vanguard Gru Inc. The United Kingdom-based Lansdowne (Uk) Limited Liability Partnership has invested 0.03% in Ingersoll-Rand Plc (NYSE:IR). Hanseatic Service Inc has 556 shares. Hemenway Comm Ltd Liability reported 4,500 shares. Aperio Gp Llc reported 0.09% of its portfolio in Ingersoll-Rand Plc (NYSE:IR). Riggs Asset Managment Co reported 0.01% of its portfolio in Ingersoll-Rand Plc (NYSE:IR). Aqr Mngmt Ltd reported 2.76 million shares. Lombard Odier Asset (Switzerland) owns 12,686 shares. Deutsche Commercial Bank Ag has 0.07% invested in Ingersoll-Rand Plc (NYSE:IR).

Analysts await Ingersoll-Rand Plc (NYSE:IR) to report earnings on April, 25. They expect $0.64 earnings per share, up 12.28% or $0.07 from last year’s $0.57 per share. IR’s profit will be $159.93 million for 34.70 P/E if the $0.64 EPS becomes a reality. After $1.02 actual earnings per share reported by Ingersoll-Rand Plc for the previous quarter, Wall Street now forecasts -37.25% negative EPS growth.

General American Investors Co Inc holds 0.01% of its portfolio in Repros Therapeutics Inc. for 237,504 shares. Baldwin Brothers Inc Ma owns 1,750 shares or 0% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 53,475 shares. The Ontario – Canada-based Bank Of Montreal Can has invested 0% in the stock. Bank Of New York Mellon Corp, a New York-based fund reported 21,773 shares.